|
1
|
Jacobsen AA, Aldahan AS, Hughes OB, Shah
VV and Strasswimmer J: Hedgehog pathway inhibitor therapy for
locally advanced and metastatic basal cell carcinoma: A systematic
review and pooled analysis of interventional studies. JAMA
Dermatol. 152:816–824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ericson MB, Wennberg AM and Larkö O:
Review of photodynamic therapy in actinic keratosis and basal cell
carcinoma. Ther Clin Risk Manag. 4:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ionescu DN, Arida M and Jukic DM:
Metastatic basal cell carcinoma: Four case reports, review of
literature, and immunohistochemical evaluation. Arch Pathol Lab
Med. 130:45–51. 2006.PubMed/NCBI
|
|
4
|
Chen L, Silapunt S and Migden MR:
Sonidegib for the treatment of advanced basal cell carcinoma: A
comprehensive review of sonidegib and the BOLT trial with 12-month
update. Future Oncol. 12:2095–2105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Unal S, Cetin M and Gumruk F: Basal cell
carcinoma after treatment of childhood acute lymphoblastic leukemia
and concise review of the literature. Pediatr Dermatol. 32:e82–e85.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Situm M, Buljan M, Bulat V, Lugović Mihić
L, Bolanca Z and Simic D: The role of UV radiation in the
development of basal cell carcinoma. Coll Antropol. 32 Suppl
2:S167–S170. 2008.
|
|
7
|
Boer B, Kopp J, Mallanna S, Desler M,
Chakravarthy H, Wilder PJ, Bernadt C and Rizzino A: Elevating the
levels of Sox2 in embryonal carcinoma cells and embryonic stem
cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic
Acids Res. 35:1773–1786. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sanada Y, Yoshida K, Ohara M, Oeda M,
Konishi K and Tsutani Y: Histopathologic evaluation of stepwise
progression of pancreatic carcinoma with immunohistochemical
analysis of gastric epithelial transcription factor SOX2:
Comparison of expression patterns between invasive components and
cancerous or nonneoplastic intraductal components. Pancreas.
32:164–170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mou W, Xu Y, Ye Y, Chen S, Li X, Gong K,
Liu Y, Chen Y, Li X, Tian Y, et al: Expression of Sox2 in breast
cancer cells promotes the recruitment of M2 macrophages to tumor
microenvironment. Cancer Lett. 358:115–123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao X, Sun B, Sun D, Liu T, Che N, Gu Q,
Dong X, Li R, Liu Y and Li J: Slug promotes hepatocellular cancer
cell progression by increasing sox2 and nanog expression. Oncol
Rep. 33:149–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao D, Pan C, Sun J, Gilbert C,
Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D,
et al: VEGF drives cancer-initiating stem cells through
VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene.
34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Basu-Roy U, Seo E, Ramanathapuram L, Rapp
TB, Perry JA, Orkin SH, Mansukhani A and Basilico C: Sox2 maintains
self renewal of tumor-initiating cells in osteosarcomas. Oncogene.
31:2270–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Lv Z, He G, Wang J, Zhang X, Lu G,
Ren X, Wang F, Zhu X, Ding Y, et al: The SOX17/miR-371-5p/SOX2 axis
inhibits EMT, stem cell properties and metastasis in colorectal
cancer. Oncotarget. 6:9099–9112. 2015.PubMed/NCBI
|
|
14
|
Alonso MM, Diez-Valle R, Manterola L,
Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de
Munain A, Sampron N, et al: Genetic and epigenetic modifications of
Sox2 contribute to the invasive phenotype of malignant gliomas.
PLoS One. 6:e267402011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kregel S, Kiriluk KJ, Rosen AM, Cai Y,
Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ and Vander Griend
DJ: Sox2 is an androgen receptor-repressed gene that promotes
castration-resistant prostate cancer. PLoS One. 8:e537012013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ling GQ, Chen DB, Wang BQ and Zhang LS:
Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in
human breast cancer cell lines. Oncol Lett. 4:1264–1268. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Ji X, Chen J, Yan D, Zhang Z, Wang
Q, Xi X and Feng Y: SOX2 enhances the migration and invasion of
ovarian cancer cells via Src kinase. PLoS One. 9:e995942014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li YJ, Dong M, Kong FM, Zhou JP, Liang D
and Xue HZ: MicroRNA-371-5p targets SOX2 in gastric cancer.
Oncotarget. 7:31993–32005. 2016.PubMed/NCBI
|
|
19
|
Wilbertz T, Wagner P, Petersen K, Stiedl
AC, Scheble VJ, Maier S, Reischl M, Mikut R, Altorki NK, Moch H, et
al: SOX2 gene amplification and protein overexpression are
associated with better outcome in squamous cell lung cancer. Mod
Pathol. 24:944–953. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruan J, Wei B, Xu Z, Yang S, Zhou Y, Yu M,
Liang J, Jin K, Huang X, Lu P and Cheng H: Predictive value of Sox2
expression in transurethral resection specimens in patients with T1
bladder cancer. Med Oncol. 30:4452013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maddison P, Thorpe A, Silcocks P,
Robertson JF and Chapman CJ: Autoimmunity to SOX2, clinical
phenotype and survival in patients with small-cell lung cancer.
Lung Cancer. 70:335–339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun L, Liu T, Zhang S, Guo K and Liu Y:
Oct4 induces EMT through LEF1/β-catenin dependent WNT signaling
pathway in hepatocellular carcinoma. Oncol Lett. 13:2599–2606.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weng J, Zhang H, Wang C, Liang J, Chen G,
Li W, Tang H and Hou J: miR-373-3p Targets DKK1 to promote
EMT-induced metastasis via the Wnt/β-Catenin pathway in tongue
squamous cell carcinoma. Biomed Res Int. 2017:60109262017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mavrou A and Oltean S: SRPK1 inhibition in
prostate cancer: A novel anti-angiogenic treatment through
modulation of VEGF alternative splicing. Pharmacol Res.
107:276–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsuoka T and Yashiro M: The Role of
PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel).
6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gu J, Wu A, Li J, Fang J, Li M, Yao Y, Ke
Y, Gu J, Chen M and You W: An assessment of World Health
Organization criteria for severe acute respiratory syndrome in
patients with cancer. Cancer. 100:1374–1378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang HC, Hsieh SC, Yang JH, Lin SY and
Sheen LY: Diallyl trisulfide induces apoptosis of human basal cell
carcinoma cells via endoplasmic reticulum stress and the
mitochondrial pathway. Nutr Cancer. 64:770–780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fernandez-Pol S, Ma L, Ohgami RS and Arber
DA: Immunohistochemistry for p53 is a useful tool to identify cases
of acute myeloid leukemia with myelodysplasia-related changes that
are TP53 mutated, have complex karyotype, and have poor prognosis.
Mod Pathol. 30:382–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wai-Hoe L, Wing-Seng L, Ismail Z and
Lay-Harn G: SDS-PAGE-based quantitative assay for screening of
kidney stone disease. Biol Proced Online. 11:145–160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Banuett F: A method to visualize the actin
and microtubule cytoskeleton by indirect immunofluorescence.
Methods Mol Biol. 638:225–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Loboda A, Nebozhyn MV, Watters JW, Buser
CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB,
Agrawal D, et al: EMT is the dominant program in human colon
cancer. BMC Med Genomics. 4:92011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van Roosmalen W, Le Dévédec SE, Golani O,
Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de
Graauw M, et al: Tumor cell migration screen identifies SRPK1 as
breast cancer metastasis determinant. J Clin Invest. 125:1648–1664.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang Y, Wu Q, Tian T, Li L, Guo X, Feng
Z, Zhou J, Zhang L, Zhou S, Feng G, Han F, et al: The influence of
SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the
PI3K/Akt signaling pathway under normoxia. Tumour Biol.
36:6083–6093. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bae KM, Dai Y, Vieweg J and Siemann DW:
Hypoxia regulates SOX2 expression to promote prostate cancer cell
invasion and sphere formation. Am J Cancer Res. 6:1078–1088.
2016.PubMed/NCBI
|
|
37
|
Belotte J, Fletcher NM, Alexis M, Morris
RT, Munkarah AR, Diamond MP and Saed GM: Sox2 gene amplification
significantly impacts overall survival in serous epithelial ovarian
cancer. Reprod Sci. 22:38–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Neumann J, Bahr F, Horst D, Kriegl L,
Engel J, Luque RM, Gerhard M, Kirchner T and Jung A: SOX2
expression correlates with lymph-node metastases and distant spread
in right-sided colon cancer. BMC Cancer. 11:5182011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu XF, Yang WT, Xu R, Liu JT and Zheng
PS: Cervical cancer cells with positive Sox2 expression exhibit the
properties of cancer stem cells. PLoS One. 9:e870922014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Herreros-Villanueva M, Zhang JS, Koenig A,
Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM,
Bujanda L and Billadeau DD: SOX2 promotes dedifferentiation and
imparts stem cell-like features to pancreatic cancer cells.
Oncogenesis. 2:e612013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L,
Liu Y, Reisfeld RA, Xiang R, Lv D and Li N: SOX2 gene regulates the
transcriptional network of oncogenes and affects tumorigenesis of
human lung cancer cells. PLoS One. 7:e363262012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weina K and Utikal J: SOX2 and cancer:
Current research and its implications in the clinic. Clin Transl
Med. 3:192014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
SOX2 promotes the migration and invasion of laryngeal cancer cells
by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep.
31:2651–2659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yoon HI, Park KH, Lee EJ, Keum KC, Lee CG,
Kim CH and Kim YB: Overexpression of SOX2 Is associated with better
overall survival in squamous cell lung cancer patients treated with
adjuvant radiotherapy. Cancer Res Treat. 48:473–482. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mavrou A, Brakspear K, Hamdollah-Zadeh M,
Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR,
Harper SJ, Bates DO and Oltean S: Serine-arginine protein kinase 1
(SRPK1) inhibition as a potential novel targeted therapeutic
strategy in prostate cancer. Oncogene. 34:4311–4319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liao Z, Wu J, Wu M, Yan Y, Wang H, Cheng C
and Tang W: The critical role of SRPK1 in EMT of human glioblastoma
in the spinal cord. Mol Neurobiol. 54:1818–1824. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu JF, Tsao YT and Hou CH:
Fractalkine/CX3CL1 induced intercellular adhesion
molecule-1-dependent tumor metastasis through the
CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma. Oncotarget.
8:54136–54148. 2016.PubMed/NCBI
|
|
48
|
Cui H, Wu S, Shang Y, Li Z, Chen M, Li F
and Wang C: Pleurotus nebrodensis polysaccharide(PN50G) evokes A549
cell apoptosis by the ROS/AMPK/PI3K/AKT/mTOR pathway to suppress
tumor growth. Food Funct. 7:1616–1627. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sun Y, Tu Y, He LI, Ji C and Cheng BO:
High mobility group box 1 regulates tumor metastasis in cutaneous
squamous cell carcinoma via the PI3K/AKT and MAPK signaling
pathways. Oncol Lett. 11:59–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Meng J, Zhang XT, Liu XL, Fan L, Li C, Sun
Y, Liang XH, Wang JB, Mei QB, Zhang F and Zhang T: WSTF promotes
proliferation and invasion of lung cancer cells by inducing EMT via
PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal.
28:1673–1682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li D, Zhao LN, Zheng XL, Lin P, Lin F, Li
Y, Zou HF, Cui RJ, Chen H and Yu XG: Sox2 is involved in paclitaxel
resistance of the prostate cancer cell line PC-3 via the PI3K/Akt
pathway. Mol Med Rep. 10:3169–3176. 2014. View Article : Google Scholar : PubMed/NCBI
|
